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ABSTRACT 
Amphotericin B is a highly effective antifungal agent and its use has been surged drastically due to its effectiveness against a wide range of fungal 
infections. It is effective against both topical and systemic infections and even this is the only drug having high efficacy against Leishmania, Candida, 
Aspergillus and many more. Owing to this, the demand of Amphotericin B is gaining momentum. However, this drug possesses numerous 
drawbacks like toxicity, poor solubility to name a few, due to which its current use is dwindling. So far the numbers of formulations have been 
marketed in order to triumph over its toxicity and solubility related issues. Unfortunately, no single study conducted hitherto gain success in 
overcoming its lethal ramifications. Among all formulations, nanoemulsions are at the top to combat all issues related to this drug. Nanoemulsion 
has shown enhanced stability, reduced cost and toxicity. This review will assimilate complete information on the use of nanoemulsion based 
formulations of Amphotericin B, its developed formulations and also will enunciate the important considerations and future perspectives. The 
complete data have been composed from Google Scholar, ScienceDirect and PubMed using the following keywords. 
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INTRODUCTION 
Fungal infection is an increasing cause of concern in today’s era as a 
wide population is affected by it. More than a billion people of the 
world are suffering from a diversity of fungal infections. Leading 
international fungal education (LIFE) portal states that more than 
80% of the human population are at the risk of fungal infections [1]. 
There can be two major categories of fungal infections affecting the 
human body i.e., Topical and systemic. The topical fungal infections are 
highly prevalent in the tropic and sub-tropic countries that are hot and 
humid. The topical infection mainly affects the skin, hair, nails and 
scalp. The second category i.e., Systemic fungal infection, is more fatal 
as it is the main cause for the increased rate of mortality and morbidity 
across the world. The systemic infections are widely prevalent in the 
countries like India, Africa and Brazil. Thus, for treating fungal 
infections variety of antifungal agents are developed to exhibit 
excellent therapeutic activity towards diseases like Aspergillosis, 
Candidiasis, Blastomycosis, Coccidioidomycosis, etc. [2]. 
For the past 30 y, Amphotericin B is considered as the choice of drug for 
the therapeutic treatment of severe systemic fungal diseases such as 
systemic candidiasis caused by yeast, overpowering the other newly 
synthesized antifungal agents. Another area associated with the use of 
Amphotericin B is in the effective treatment of visceral leishmaniasis, 
commonly known as kala-azar. So far, Amphotericin B is the only agent 
that has proven to be effective against visceral leishmaniasis. 
Amphotericin B can be administered into the body through different 
routes for procuring the desired results in treating the fungal infections. 
Topical and intravenous administrations are the major routes associated 
with the delivery of Amphotericin B into the body. In the case of topical 
fungal infections, topical delivery of the drug is the most efficient route 
for treatment. Topical application is preferred as the drug is in direct 
contact with the infected part of the body and easily penetrates into the 
stratum corneum of the skin, which shows fungicidal or the fungi-static 
activity as the desired cure for the infection [3]. Various marketed 
formulations available for topical treatment include Fungizone cream, 
Fungizone lotion, Fungizone ointment and Fungisome liposomal gel for 
the topical administration of amphotericin B.  
Nowadays, for the safe and effective delivery of the Amphotericin B 
topical route is highly preferred in the treatment of fungal infections 
located on the local surface. As discussed above, an Amphotericin B gel 
(Fungisome) and a lotion (Fungizone) is available in the market for 
treating topically different fungal infections such as skin infections, 
fungemia, cutaneous leishmaniasis, etc. But there are some confines 
for these formulations that include very less skin permeability and the 
clinical efficacy limitation. However, in the case of systemic fungal 
infections and the visceral leishmaniasis, the preferred route of 
administration is parenteral. Parenteral delivery is preferred as the 
drug directly reaches the systemic circulation and kills the fungal 
agents or inhibits its growth. Different formulations like Ambiosome, 
Phosome, Abelcet, Amphocil, Anolip to name a few, have been 
marketed for parenteral administration of the Amphotericin B. These 
formulations suffer from the drawback of having high toxicity and high 
cost. Firstly, the drug itself has high nephrotoxicity and secondly, 
incorporation of high content of surfactants to develop a formulation 
further boosted up its toxicity issues. The use of surfactants is required 
to form the suitable formulation, which is the main hurdle due to the 
physiochemical properties of drug molecules.  
Physiochemical properties of 'Amphotericin B' 
The drug possesses high molecular weight and bulky structure, which 
are the main reasons that affect the formulation development. The 
structure of the molecule consists of a hydroxyl rich hydrophilic chain 
and a hydrophobic heptane chain, which shows decreased solubility 
effects in hydrophobic as well as aqueous systems resulting in decreased 
skin permeation effects. The drug is amphiphilic in nature, which is the 
foremost hurdle to be overcome in designing of an effective delivery 
system. Consequently, the need for modifying the existing dosage form is 
necessary to formulate a novel delivery system [4]. 
Evolution in amphotericin b delivery systems 
Amphotericin B is amphiphilic in nature due to which the formulation 
development of the drug offers a number of hindrances. As the 
hydrophobicity of Amphotericin B is very high and the conventional 
parenteral formulation uses a very high concentration of sodium 
deoxycholate as a solublizer i.e., 65% w/w in the formulation, which 
offers some pitfalls as an intravenous drug delivery such as 
nephrotoxicity, anemia, cardiotoxicity, hypotension, anorexia, dyspnea, 
fever, nausea, chills, vomiting, pain at the injection site, electrolyte 
abnormalities and hepatotoxicity. Fungizone is the licensed formulation 
available in the market, which consists of the surfactant with 
Amphotericin B, phosphate buffer and sodium deoxycholate. As only 
parenteral administration of this drug is effective for the treatment of 
systemic infections due to its low bioavailability and solubility, the 
scientists emerged with the need to formulate such a dosage form. In the 
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succeeding years, various lipid-based formulations were developed in 
the form of colloidal dispersions or lipid complexes. Though these 
formulations claimed for the decreased toxicity than the previous 
formulation still were found to exhibit adverse effects over the 
phagocytes rich organs. Finally, in the year of 1998, a liposome based 
formulation also known by the name Ambisome was developed. This 
was claimed to be a better approach than the previous formulations 
because they added lipid bilayer stability, drug being entrapped for an 
increased time period, highly targeted, exterminate toxicity and reduced 
side effects. The increase in the administered dosage increases the 
adverse effects related to the drug; thus, the amount of the drug to be 
administered in the body must be optimized for its safe, efficacious and 
effective use. 
Therefore, the most desirable modification was performed a decade ago 
on Amphotericin B where the physical characteristics of the drug were 
altered, which finally depicted enhanced efficacy when compared to 
Fungizone. From that point of time the emphasis was highly shifted 
towards the development of various lipoidal formulations with effective 
therapeutic activity in combination with the declined toxicity effects. The 
methods to achieve the desired results deal with the alteration of the 
drug molecule and its delivering models. The delivery of Amphotericin B 
has been further modified by combining it with other agents and 
determine its synergistic effects and interactions. Amphotericin B has 
also been administered as an aerosol preparation through the intranasal 
route for drug delivery [5]. 
Ehrlich gave the concept of “magic bullet” in drug delivery, which is the 
term he coined for medicine. According to the previously defined ideal 
characteristics of a dosage form, a delivery system should act in such a 
manner so as to target its desired site and show the maximum 
therapeutic effect and minimum adverse effects. Therefore, the 
researchers aimed at developing such a dosage form of amphotericin B 
that will successfully target the specified area and act on it with the least 
side effects. In lieu of this, Nanoemulsions of Amphotericin B were 
developed for topical and systemic delivery that have been altered to 
such an extent that they exhibit the minimum side effects, decreased 
toxicity, enhanced stability, safety and enhanced targeting therapeutic 
action [6]. Among all formulations developed so far, Nanoemulsions 
were only carriers, which have shown the best results with reduced cost. 
Nanoemulsions 
Nanoemulsions are identified as submicron emulsion, mini-
emulsions and ultrafine emulsions that are nanosized colloidal 
particles. This dosage form is kinetically as well as 
thermodynamically stable dispersion, consisting of two non-miscible 
liquids (eg., Oil and water), an appropriate surfactant and co-
surfactant that helps in stabilization of the film between the 
interface of the two liquids so as to form a single-phase formulation 
[7]. The size of the nanoemulsion droplet ranges between 5-100 nm. 
The modifications in the size of the nanoemulsion can lead to 
uncommon elastic behavior and optical transparency [8]. The 
components used in the formation of nanoemulsion must be 
categorized as “generally recognized as safe (GRAS)” by the United 
States Food and Drug Administration (FDA) [9]. The surfactants 
used in formulating the nanoemulsion must possess varied 
characteristics to enlist; some are non-toxic, compatible with other 
raw materials, non-irritant, etc. Surfactants widely used includes 
Sorbitan esters, polysorbates (nonionic), sodium lauryl sulfate, 
potassium laurate (anionic), quaternary ammonium halide 
(cationic) and some Zwitterionic surfactants. The site-specificity of 
the nanoparticles can be enhanced by magnetizing the delivery 
system. The major goal of a delivery system must target in excelling 
its therapeutic efficacy and causing declination of toxicity and side 
effects [10]. Depending on the composition three types of 
nanoemulsions are formed; First one is the, oil in water (O/W) 
nanoemulsion in which the aqua is the continuous phase and oil is the 
dispersed phase, second is the water in oil (W/O) nanoemulsion in 
which the water acts as the dispersed phase and the oil being 
continuous phase and lastly, bi-continuous nanoemulsion in which the 
oil and water are interspersed with each other in the system [11]. 
Composition of nanoemulsion 
The major three components of a nanoemulsion include oils, 
surfactants/Co-surfactant and an aqueous phase. The nanoemulsion 
formulation is a colloidal dispersion consisting of an aqueous phase, 
surfactant, oil phase and a co-surfactant in appropriate ratios. Some 
of the oils, surfactants and co-surfactants combination for the 
development of nanoemulsions is shown in table 1. 
  
Table 1: Various combinations used for the development of nanoemulsions 
Oils Surfactants Co-surfactants Outcome Reference 
Triacetin Cremophor EL Butanol Decreased oral toxicity and depicted highly efficacious 
insecticidal activity. 
[12] 
Capryol 90: Vitamin 
E 
Tween 80 Transcutol-HP Naringenin nanoemulsion development for nose to brain 
drug delivery system. Efficacious anti-Parkinson therapeutic 
effects with enhanced bioavailability and efficacy.  
[13] 












Tween 80 Ethanol and 
propylene glycol 
The outcome of this study resulted in successfully exhibiting 
the antioxidant activity present in the Tocotrienols and 
enhanced stability for a large time period. 
[15] 
Oleic acid Labrasol PEG 400 Enhancement of bioavailability with effective and efficient 
targeting to the brain.  
[16] 
Capryol 90 Poloxamer 188 Tween 80 Enhanced bioavailability, Accurate dosing and decreased 
toxicity of Itraconazole were obtained.  
[17] 
Nigella sativa seed 
essential oil 
Tween 80 Polysorbate 80 Decreased cell viability with targeted drug delivery depicting 
anti-cancerous activity. 
[18] 
Miglyol 812 Tween 80 Labrasol The nanoemulsion formulated depicted enhanced 
bioavailability of Fisetin with decreased Labrasol toxicity, 
improved anti-tumoral and anti-angiogenic activity. 
[19] 
Flaxseed oil Egg 
phosphatidylcholine 
Deoxycholic acid Efficacious anti-tumor and anti-cancer therapeutic effects 
with enhanced bioavailability and decreased acute toxicity.  
[20] 
Peppermint oil Tween 80 Ethanol This depicted the enhanced bioavailability of Carvedilol in 
the body, increasing its solubility in the respective oil. 
[21] 
Lauroglycol-90 Transcutol-HP Isopropyl alcohol The nanoemulsion formulated depicted enhanced anti-
cancerous effects. 
[22] 
Capmul MCM Tween 80 Polyethylene 
glycol 400 
Decreased nasal cilio-toxicity and increased diffusion were 
obtained from the developed nanoemulsion. 
[23] 
Sefsol-218 Tween 80 Carbitol Development of stable nanoemulsion with increased 
bioavailability of Ramipril. 
[24] 
Peanut oil Tween 80 and 
Cremophor EL 
Transcutol P and 
PG 
It depicted high bioavailability of Acetazolamide in the eye 
successfully treating glaucoma with the associated prolonged 
effect on the eye. 
[25] 
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The HLB value of formulated nanoemulsion is an important 
parameter of consideration. HLB value stands for hydrophilic-
lipophilic-balance which determines the ratio of the lipophilic and 
hydrophilic regions present in the moiety and helps in defining the 
oil or water affinity with the surfactant. The nanoemulsion 
formulation is an advantageous one as it shows decreased interfacial 
tension than the coarse emulsions [26]. Co-surfactants are the main 
components that help with the resultant low interfacial tension. 
Thus, forms a nanoemulsion which is stable thermodynamically. 
Droplet size is below 140 nm forming transparent formulation. A 
variety of administration routes are known, but a large emphasis is 
towards the topical administration of the nanoemulsions. Drug-
vehicle mobility, drug release and the drug permeation through the 
skin are the three major aspects to determine transdermal drug 
permeation. Therefore, nanoemulsions depict enhanced transdermal 
delivery. The skin permeation of nanoemulsion gels is decreased due 
to its viscosity and in such comparisons nanoemulsion formulations 
are more effective for the permeation into the skin. Due to the 
increase in lipophilic and hydrophilic drug’s solubilisation potential, 
the transdermal flux of nanoemulsion formulation has gained 
superiority and hence, increasing the thermodynamic action on skin 
and drug permeability. In such scenarios, the nanoemulsion 
constituents act as enhancers of permeation. By altering the stratum 
cornea’s structure, the permeation through the skin can be 
improved. As depicted in fig. 1, Nanoemulsions possess various 
merits and demerits as drug delivery systems. 
 
 
Fig. 1: Nanoemulsion formulation pros and cons 
 
Factors to be considered during the formulation of nano-
emulsions 
Primarily, the most essential element of nanoemulsion is the 
surfactant that is unable to develop lyotropic liquid crystalline 
“microemulsions” phases. Short-chain alkanes, water, surfactants 
and alcohols when used along with co-surfactant forms such phases 
in a solitary system. Secondly, Ostwald ripening must be avoided 
using the appropriate amount of components. The dispersion 
medium and dispersed phase must not be soluble in one another 
and lastly, the coalescence must be removed by using high amounts 
of surfactants to enable rapid coating in the process of 
emulsification [10]. 
Nanoemulsion for delivery of amphotericin b 
Topical delivery via nanoemulsion 
In recent years, a bulk of a topical dosage form of Amphotericin B 
has been developed in different forms, such as creams, lotions, gels. 
The demand for the topical dosage form has been increased for 
delivering Amphotericin B in the treatment of various fungal 
infections.  
In year 2012, topical nanoemulsion of amphotericin B was 
developed. In this article, the topical delivery of the amphotericin 
B was tested by loading it in nanoemulsion. The permeation 
studies were conducted in vitro on dermal models. The 
nanoemulsion developed to depict low particle size and enhanced 
encapsulation efficiency. The Amphocil provided the best ever 
results of the skin penetration and hence, the activity towards 
fungal infections [27]. 
In the year 2014, another topical formulation was developed that 
was cost-effective and showed sustained release of the drug. By 
varying the composition of the components and using the titration 
method the nanoemulsions were formulated. Different evaluations 
of particle size, permeability, zeta potential, stability and skin 
deposition were performed. The final results stated that the 
formulation developed can be used as an effective, safe and efficient 
approach in the fungal infection treatment [28]. 
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In the year 2015, a vitamin E TPGS nanogel of amphotericin B was 
developed. It was highly beneficial in the treatment of cutaneous 
fungal infections. The developed nanoemulsion was similar in 
strength to the marketed formulations and was efficiently optimized 
by the pseudo-ternary phase diagrams. The Smix ratio, co-surfactant, 
surfactant, size distribution, viscosity, rheology and percent 
transmittance are the parameters that were optimized. This 
formulation exhibited increased deposition on the skin. Confocal 
laser scanning microscopy (CLSM) determined the distribution of 
the formulation deeper into the skin [4]. 
In the same year, another research for nanoemulsion development 
was carried out for treating topical fungal infection. Chalcones were 
the main components that were used in their development. These 
are very less water-soluble compounds. The full factorial design was 
used to optimize the dosage form in the effective treatment of 
cutaneous leishmaniasis. The formulation was developed using the 
process of spontaneous emulsification. Stability studies were 
performed using an antileishmanial assay against different strains of 
Leishmania. The final results confirmed its activity against the 
cutaneous leishmaniasis [29]. 
Till this time, the research towards the nanoemulsion formulation 
has reached unprecedented levels and more to be accomplished. 
Further, in the year 2016 an amphotericin B gel was formulated 
depicting antifungal activity and further testing it for its in vivo 
and in vitro activity. The gel formulated in this attempt was made 
using different ratios of the polymer. The results of this article 
depicted that the dosage form formulated shows no interactions 
and contains a pure drug. The formulation was also tested for pH, 
drug content, particle size and drug release profiles. The best 
formulation was screened and found to be stable with the drug 
content of 98.12% [30].  
In the same year further, another nanoemulsion gel was prepared by 
the following components sefsol-218, Transcutol and tween 80 
using slow spontaneous titration processes. Further the 
nanoemulsion was incorporated into the gel and the particle size, 
rheology, charge, release profile, hemolytic and permeability studies 
were performed. Confocal laser scanning microscopy determined 
the irritability and permeability studies. It was concluded that it 
shows decreased toxicity and can be effectively used in the 
treatment of fungal skin infections [28]. 
Further, in the same year, a nanoemulsion gel was formulated and 
evaluated for its topical antifungal activity. The components for 
developing this nanoemulsion include Capmul, Labrasol, and 
Polyethylene glycol-400 and drug amphotericin B. The 
nanoemulsion was evaluated for particle size, zeta potential, 
polydispersity index and zone of inhibition. The release studies were 
performed using Franz diffusion cell. Fungisome is the marketed 
formulation of nanoemulsion gel of amphotericin B. The optimal 
formulation was safe, stable, sustained and effective [28]. 
Further in the year 2017, a topical nanoemulsion of amphotericin B 
was formulated for curing the skin infections such as candidiasis and 
aspergillosis. In this article, the nanoemulsion formulated consists of 
those components which show desired solubility and compatibility 
studies. Further, by the use of pseudo-ternary phase diagram the 
best formulation was screened. Finally, after formulating the dosage 
form various studies, like stability, permeation in the skin, release of 
the drug, antifungal effect and skin retention capacity was 
performed. The results determined that the formulation developed 
is optimized for topical usage [31].  
In the same year, another research was progressing, nanoemulsion 
formulation of amphotericin B was developed using lipids and 
surfactants. The process of slow and spontaneous titration was used 
for its formulation. Different evaluation parameters were tested, 
which included zeta potential, polydispersity index, zone of 
inhibition, skin permeation and deposition studies, particle size and 
histopathology. When it was compared to the conventional dosage 
form it exhibited activity without toxicity. A zone of inhibition values 
is a good method of showing increased safety and efficacy for the 
treatment of fungal infections [32]. 
In the year 2018 another nanoemulsion for topical administration of 
amphotericin B was developed. Amphotericin B exhibits a positive 
action as a polyene antifungal agent. The mechanism of action 
followed by this includes the fungal cell wall disruption by binding 
to sterols leading to pore formation and, thus, leakage of the 
components of the cell. The nanoemulsion gel was formulated by 
altering the ratio of the polymer. The different analysis test proved 
the drug purity, no interactions between chemicals, pH, drug 
content, release profiles and particle size. The best-optimized 
formulation depicted stability with the drug content 93.92% [7]. 
Intranasal delivery via aerosols 
Varying routes are available for the administration of the drug-using 
different types of drug delivery systems. In the year 2012, lipid 
nanoemulsion of amphotericin B was developed for delivery 
through pulmonary route. There are two already available lipid 
nanoemulsions i.e., Intralipid and Clinoleic. The formulation was 
finally evaluated for zeta potential, particle size, loading efficiency, 
drug content and particle fraction. This article determines that the 
lipid nanoemulsion of amphotericin B is an excellent modification 
for intranasal delivery in the form of a nebulizer [33]. 
Intravenous delivery via nanoemulsion 
Till date different lipid formulations of amphotericin B are available 
under various marketed names, Ambiosome being the most popular 
one.  
In the year 2003, a lipid nano-sphere emulsion was developed that 
was shown to exhibit low dose therapeutic action for delivering 
amphotericin B to its site of action. It was a homogenous emulsion 
which showed high plasma concentration and was much more 
effective than Fungizone in the treatment of systemic infections. 
Thus, it was an effective dosage form for the low dose delivery to the 
desired site of action [34]. 
In the year 2013, the first approach towards the intravenous 
treatment of visceral leishmaniasis was practiced. In this article, the 
Chitosan nanocapsules incorporating Amphotericin B were 
developed with the help of polymer deposition technique. They 
depicted good stability as Chitosan helped in preventing the 
destabilization. It was less toxic than the Fungizone and Ambisome. 
The final result suggested that it is an efficient dosage form to be 
administered with chemotherapy and is low in cost [35]. 
Intravenous delivery of drugs is a preferred dosage form for 
treatment of systemic fungal infection. In the year 2015, 
Amphotericin B nanoemulsions were formulated consisting of a 
lipophilic amine, cholesterol and the drug. The formulation 
developed was optimized by testing it for stability, retention of drug, 
absorption studies, toxicity studies and circular dichroism data. The 
product finally formulated shows the desired in vitro anti-
leishmanial action [36]. 
In the year 2018, the article main focus was to develop a nanoemulsion 
and optimize it to give efficacious results. The developed formulation 
was further tested for hemolytic toxicity and the anti-leishmanial 
activity. The formulation was evaluated for the particle size, 
polydispersity index and encapsulation efficiency. The formulation was 
tested against the strains that cause visceral leishmaniasis. The final 
results showed a decrease in the hemolytic toxicity and positive anti-
leishmanial activity, thus characterizing the formulation to be effective in 
the treatment of visceral leishmaniasis [37]. 
Toxicity associated with amphotericin b and alternatives to 
reduce its toxic levels 
Amphotericin B is the only drug known to be effective towards 
leishmaniasis. Therefore, it is a drug of great significance. 
Nonetheless, the drug expresses a large number of adverse effects 
on the human body. The acute toxicities observed by the drug-
deoxycholate complex include fever, nausea, vomiting, rigors, 
hypertension, hypotension, hypoxia, flank and urticaria. Further, 
some of the chronic toxicities related to the drug are cardiotoxicity 
and nephrotoxicity, which resulted in the increased blood urea 
nitrogen and serum creatinine levels, which when treated with 
Kaur et al. 
Int J App Pharm, Vol 12, Issue 5, 2020, 1-6 
5 
 
liposomal formulation of Amphotericin B exhibited alleviation of 
azotemia. Hyperphosphatemia, anemia and thrombocytopenia are 
the other minute toxicities seen with Amphotericin B. The various 
alternatives to reduce the drug toxicity includes combining it with 
the liposomes to reduce the chronic toxicity (the first-ever liposomal 
formulation of Amphotericin B was developed in the year 1990), 
administering sodium chloride hours before administration of 
Amphotericin B results in decreased levels of nitrogen, Conjugating 
Amphotericin B with Arabinogalactan and regular monitoring of 
electrolytes, phosphates and magnesium [38, 39, 40]. 
Future prospects 
The nanoemulsion seems to be a holistic approach for delivery of 
Amphotericin B. The development of antifungal nanoemulsion is 
proliferating and will reach out to various advantageous prospects. 
The nanoemulsion employed as a carrier and if to emphasize with 
further research deemed to be an efficient carrier with cheaper cost 
than the already available marketed Amphotericin B formulations. 
The cost-effectiveness of this emulsion-based system would act as 
one of the factors for it is the preferred medication for treatment of 
severe fungal infections as the majority of the population cannot 
afford such costly medications. Another advantage of the 
nanoemulsion is its stability as it is highly stable than the available 
marketed liposomal liposomal Amphotericin B formulation 
Furthermore, these systems tend to plunge the toxicity issues 
associated with this drug. So, in future this formulation would act as 
the standard to treat severe fungal infections. 
CONCLUSION 
To conclude, Amphotericin B is highly hydrophobic in nature, 
resulting in decreased solubility of the drug and its bioavailability. 
This review has targeted all the available dosage forms of 
Amphotericin B and the difficulties crossed during the development 
of any dosage form. This review is mainly pointed towards the 
development of such a dosage form, which would be cost-effective, 
safe and highly stable, exhibiting similar actions as that of the other 
dosage forms with the best results. The area of interest here leads 
towards the nanoemulsion development of Amphotericin B. Though 
the drug shows numerous adverse effects the development of 
nanoemulsion would result in diminishing the reactions as it uses a 
small and specified amount of surfactants which, when used in high 
amounts was the reason causing the urticaria, fever, hypoxia, 
hypertension, etc. As Amphotericin B is the only standard drug for 
the treatment of leishmaniasis, there arises a high need to develop a 
formulation which is cheaper at cost, patient compliant, easily 
affordable and effective towards the treatment of the disease.  
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